Back to Newsroom

Pharnext Completes Patient Enrollment in International Pivotal Phase 3 Trial of PXT3003 for Charcot-Marie-Tooth Disease Type 1A

Paris, December 20th , 2016 – Pharnext SA (FR00111911287 – ALPHA), a French biopharmaceutical company developing an advanced portfolio of products in the field of neurodegenerative diseases, today announced that it has completed patient enrollment for its international pivotal Phase 3 PLEO-CMT trial of PXT3003, Pharnext’s lead PLEODRUG© , for the treatment of Charcot-Marie-Tooth Disease Type 1A (CMT1A).

Click here to read the full release